White & Case (Washington)

Jaclyn Phillips

White & Case (Washington)
Lawyer (Associate)

Jaclyn Phillips is an associate in the firm’s Global Antitrust/Competition practice group, who focuses on complex litigation in the areas of antitrust, intellectual property, and class actions. She has notable appellate experience, and counsels clients on antitrust issues. Jaclyn represents several leading global pharmaceutical companies, including Allergan and Boehringer Ingelheim, in class action litigation matters at the cutting edge of antitrust and intellectual property. Jaclyn also has an extensive pro bono practice, with a particular focus on immigration matters. She has represented clients who were granted asylum in the United States. Jaclyn graduated from Georgetown University Law Center cum laude in 2013, where she served as an Articles & Notes Editor on the American Criminal Law Review.

Linked authors

White & Case (Brussels)
White & Case (Washington)
White & Case (New York)
White & Case (Washington)
White & Case (New York)

Articles

2662 Bulletin

Mark J. Gidley, George Paul, Rebecca H. Farrington, Nicholas Putz, Jaclyn Phillips, Chenyuan Fu The US FTC starts issuing "Pre-Consummation Warning Letters" for transactions investigations which may need to remain open beyond the regular HSR waiting period

289

On Tuesday, August 3, 2021, the Federal Trade Commission announced a new approach for merger investigations that the FTC does not complete during the Hart-Scott-Rodino Act (HSR) waiting period—the FTC may advise merging parties via a Warning Letter that its investigation remains open despite the (...)

Michael Gallagher, Kristen O’Shaughnessy, Kathryn Jordan Mims, Kevin Adam, Jaclyn Phillips The US President Joe Biden publishes an executive order containing 72 initiatives to address competition concerns in several industries, including pharmaceuticals, biotech, and healthcare

634

Citing concerns about growing consolidation, reduced competition, and increasing prices, President Biden issued on July 9, 2021 a sweeping Executive Order containing 72 initiatives to address competition concerns in a number of industries, including pharmaceuticals, biotech, and healthcare. In (...)

Mark J. Gidley, George Paul, Jack E. Pace, Kathryn Jordan Mims, Kristen O’Shaughnessy, Kevin Adam, Jaclyn Phillips, Abdul Hafiz, Erin McNamee The US President Joe Biden signs an executive order instructing more than a dozen federal agencies to promptly tackle some of the most pressing competition problems across the national economy

500

A new Executive Order signed by President Biden includes 72 initiatives instructing more than a dozen federal agencies, including the US Department of Justice and the Federal Trade Commission, to, according to the White House’s Fact Sheet, "promptly tackle some of the most pressing competition (...)

Mark J. Gidley, Kathryn Jordan Mims, Kristen O’Shaughnessy, Erin McNamee, Kevin Adam, Jaclyn Phillips, Abdul Hafiz, Tal Marnin The US President Joe Biden signs an executive order which includes 72 initiatives aimed at enhancing competition and a directive encouraging the US FTC to ban or limit employee non-compete agreements

155

On Friday, July 9, 2021, President Biden signed Executive Order 14036, Promoting Competition in the American Economy, which includes—among 72 initiatives aimed at enhancing competition in the US—a directive encouraging the Federal Trade Commission to ban or limit employee non-compete agreements. (...)

Noah A. Brumfield, Kevin Adam, Jaclyn Phillips, Chenyuan Fu The US President Joe Biden signs an executive order containing 72 initiatives seeking to coordinate the federal government’s response to what it sees as pressing competition issues and the threat in the rise of large corporations

142

Calls for changes to antitrust law, and how antitrust laws should be applied to the conduct of large technology companies, have been heating up in recent years. Now, the push for wide-scale changes to antitrust law has reached a boiling point. Indeed, President Biden’s sweeping July 9, 2021 (...)

Mark J. Gidley, George Paul, Rebecca H. Farrington, Martin M. Toto, Kathryn Jordan Mims, Michael E. Hamburger, Daniel Rosenthal, Adam Acosta, Jaclyn Phillips The US State of New York Senate adopts a legislation prohibiting abuse of dominance and requiring new thresholds for the State’s pre-merger notification system

212

While Congress has been the epicenter of an ongoing antitrust debate—with US legislators on both sides of the aisle urging vast reforms—the New York State legislature is pursuing a state bill that would arguably ensnare more conduct and transactions in antitrust law’s web than anything proposed, (...)

Mark J. Gidley, Martin M. Toto, Kathryn Jordan Mims, Jaclyn Phillips, Trina Shek Rizzo, Michael Mahaffey The US DoJ issues its first business review letter under the DoJ-FTC expedited COVID-19 competitor collaboration review procedures, blessing several medical supply companies to work together to produce and distribute protective equipment

143

On April 4, 2020, the Antitrust Division of the Department of Justice issued its first Business Review Letter under the DOJ-FTC joint expedited COVID-19 competitor collaboration review procedures, blessing several medical supply companies to work together to produce and distribute personal (...)

Jaclyn Phillips, Trina Shek Rizzo, Kathryn Jordan Mims, Mark J. Gidley The US Senate passes the CARES Act as a response to the COVID-19 crisis and tackles numerous issues on several fronts to stabilise the economy

66

The Coronavirus Aid, Relief, and Economic Security ("CARES") Act provides no modifications to, or relief from, the US antitrust laws (specifically, the Sherman Act, 15 U.S.C. §§ 1-38; Clayton Act, 15 U.S.C. § 12-27; and Robinson-Patman Act, 15 U.S.C. § 13). But some major businesses are forming (...)

Send a message